ASX-listed Proteomics has joined forces with England’s revered Oxford University as the medtech continues to study its blood test for the diagnosis of endometriosis.
The Company’s prototype “PromarkerEndo” blood test has previously correctly identified up to 90 percent of patients with endometriosis from a study of more than 900 patients.
Management says it has now signed a material transfer agreement with the University of Oxford to acquire 600 clinical plasma samples to continue its study into its blood test to identify the debilitating disease.
